带状疱疹疫苗市场规模、份额和成长分析（按产品类型、疫苗类型和地区划分）－2026-2033年产业预测

预计到 2024 年，带状疱疹疫苗市场规模将达到 40.6 亿美元，到 2025 年将达到 43.6 亿美元，到 2033 年将达到 78.4 亿美元，预测期（2026-2033 年）的复合年增长率为 7.6%。

带状疱疹疫苗市场持续扩张，主要驱动因素是60岁及以上人口患带状疱疹的风险不断增加，以及已开发国家医疗政策的发展。在美国，大约三分之一的人一生中会患上带状疱疹，因此主要国家都建议推广接种疫苗。带状疱疹疫苗接种的重要性已被公认为一项重要的预防性措施。儘管重组疫苗高成本，但其创新仍在推动市场成长。监管机构建议使用欣格瑞（Shingrix）疫苗，因为它比传统疫苗更有效，这一趋势在包括加拿大和澳洲在内的多个国家都有体现。随着带状疱疹病例老龄化增长而增加，预计疫苗需求将持续增长，这凸显了疫苗接种在疾病预防中的重要作用。

带状疱疹疫苗市场驱动因素

带状疱疹在全球日益普遍，是推动带状疱疹疫苗市场扩张的主要因素。随着人口老化，罹患带状疱疹及其併发症的风险也相应增加。这种人口结构变化凸显了采取有效预防措施以遏制带状疱疹发病率的紧迫性。因此，医疗系统和个人层面都越来越意识到接种疫苗的重要性，从而导致带状疱疹疫苗的需求不断增长。这种对预防性医疗保健措施必要性的日益增强的认识和理解，在推动市场成长方面发挥关键作用。

限制带状疱疹疫苗市场的因素

带状疱疹疫苗市场面临许多挑战，阻碍了其成长潜力。儘管强烈建议接种疫苗，但各地的接种率仍然低得令人失望。这种犹豫不决源于多种因素，包括公众对疫苗益处的认知不足、对疫苗必要性的怀疑以及对可能副作用的担忧。这些障碍不仅阻碍了人们接种疫苗，也导致市场成长停滞，从而妨碍了有效控制带状疱疹传播的努力，并限制了受影响地区公共卫生状况的整体改善。

带状疱疹疫苗市场趋势

带状疱疹疫苗市场呈现显着上升趋势，主要受带状疱疹感染病例增加（尤其是在老年人中）的推动。随着人们对带状疱疹潜在併发症的认识不断提高，医疗保健提供者和患者越来越重视接种疫苗作为预防措施。疫苗有效性和安全性的提升进一步推动了需求的成长。此外，旨在教育大众了解疫苗接种重要性的公共卫生宣传活动也促进了市场成长。因此，在人口结构变化和对预防性医疗保健日益重视的推动下，带状疱疹疫苗市场预计将迎来强劲成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术进步
• 监管环境
• 案例研究

全球带状疱疹疫苗市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 定序
• 佐斯塔瓦克斯
• 天空之星

全球带状疱疹疫苗市场规模（按疫苗类型和复合年增长率划分）（2026-2033 年）

• 重组疫苗
• 减毒活病毒疫苗

全球带状疱疹疫苗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• GlaxoSmithKline（GSK）
• Merck & Co., Inc.
• Pfizer Inc.
• BioNTech SE
• SK bioscience
• GeneOne Life Science
• Curevo Inc.
• Vaccitech
• Jiangsu Recbio Technology Co., Ltd.
• Changchun BCHT Biotechnology Co.

结论与建议

Shingles Vaccine Market size was valued at USD 4.06 Billion in 2024 and is poised to grow from USD 4.36 Billion in 2025 to USD 7.84 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The shingles vaccine market is expanding, significantly driven by the increased risk of shingles in individuals aged 60 and above and advancements in healthcare policies across developed nations. Roughly one in three people in the U.S. will encounter shingles in their lifetime, with major countries endorsing vaccination initiatives. The importance of shingles vaccination has been recognized as essential preventive care. Innovations in recombinant vaccines are enhancing market growth, despite their higher costs. Regulatory bodies favor Shingrix over previous options due to its superior efficacy, a trend mirrored in various countries such as Canada and Australia. As cases of herpes zoster rise with age, the demand for vaccines is set to increase, emphasizing the critical role vaccination plays in disease prevention.

Top-down and bottom-up approaches were used to estimate and validate the size of the Shingles Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Shingles Vaccine Market Segments Analysis

Global Shingles Vaccine Market is segmented by product, vaccine type and region. Based on product, the market is segmented into shingrix, zostavax and skyzoster. Based on vaccine type, the market is segmented into recombinant vaccine and live attenuated vaccine. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Shingles Vaccine Market

The increasing global prevalence of shingles serves as a major catalyst for the expansion of the shingles vaccine market. As populations age, there is a corresponding rise in the risk of developing shingles and experiencing complications associated with the condition. This demographic shift highlights the urgent need for effective preventive solutions to combat the incidence of shingles. Consequently, healthcare systems and individuals are becoming more aware of the importance of vaccination, leading to greater demand for shingles vaccines. This growing awareness and recognition of the need for preventive healthcare measures play a crucial role in driving market growth.

Restraints in the Shingles Vaccine Market

The Shingles Vaccine market experiences notable challenges that hinder its growth potential. Despite the robust endorsements for vaccination, the uptake in various regions continues to be disappointingly low. This hesitance can be attributed to several factors, including insufficient public awareness regarding the benefits of the vaccine, skepticism about its necessity, and apprehensions related to possible side effects. These barriers not only deter individuals from getting vaccinated but also contribute to a stagnation in market expansion, impeding efforts to combat the prevalence of shingles effectively and limiting overall public health improvements in affected areas.

Market Trends of the Shingles Vaccine Market

The shingles vaccine market is experiencing a significant upward trend, primarily fueled by the rising incidence of shingles infections, especially within the aging population. As awareness grows regarding the potential complications associated with shingles, healthcare providers and patients are increasingly prioritizing vaccination as a preventive measure. This growing demand is further supported by advancements in vaccine technology, enhancing both efficacy and safety profiles. Additionally, public health campaigns aimed at educating individuals about the importance of vaccination are contributing to market growth. Consequently, the shingles vaccine market is poised for robust expansion, driven by demographic shifts and an increasing focus on preventive healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Shingles Vaccine Market Size by Product & CAGR (2026-2033)

• Market Overview
• Shingrix
• Zostavax
• Skyzoster

Global Shingles Vaccine Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Recombinant Vaccine
• Live Attenuated Vaccine

Global Shingles Vaccine Market Size & CAGR (2026-2033)

• North America (Product, Vaccine Type)
  • USA
  • Canada
• Europe (Product, Vaccine Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Vaccine Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Vaccine Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Vaccine Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaccitech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Changchun BCHT Biotechnology Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations